Clarithromycin versus metronidazole in first-line Helicobacter pylori eradication. Prospective randomized study of 85 Tunisian adults

##plugins.themes.academic_pro.article.sidebar##

Published Jan 30, 2012
Download
pdf
Vol. 90 No. 1 (2012): Issue Jan 2012

##plugins.themes.academic_pro.article.main##

Hichem Loghmari
Fethia BDIOUI
Wided Bouhlel
Wissem Melki
Olfa Hellara
Nabil Ben Chaabane
Leila Safer
Abdelfettah Zakhama
Hamouda Saffar

Abstract

Background: Although primary resistance to metronidazole remains high (56,8%), it is more widely used than clarithromycin as a firstline Helicobacter pylori (H. pylori) treatment in the common Tunisian practice.
Aim: To compare the eradication rate in two protocols including clarithromycin versus metronidazole in Tunisian adults.
Methods: From July 2005 to December 2007, 85 patients aged 18 to75 years presenting with gastro-duodenal lesions with H. pylori infection and requiring its eradication were included in the study. They were randomized to receive alternatively a seven-day triple therapy including: Omeprazole + Amoxicillin + Clarithromycin (OAC group) or Metronidazole (OAM group) twice a day. A second endoscopy with new biopsies was carried out 6 weeks after treatment to control eradication.
Results: Eighty five patients finished the protocol. The OAC and OAM groups included 46 and 39 patients respectively. They were comparable with respect to age, gender, clinical presentation and initial lesions. The total eradication rate was 60%. It was significantly higher in the clarithromycin group (69.6%) than in the metronidazole group (48.7%): p < 0.05.
Conclusion: Clarithromycin is more effective than metronidazole in H. pylori eradication. It should be made available in our hospital’s nomenclature. This would prevent iterative eradication courses and probably reduce treatment cost.

Keywords:

Helicobacter pylori, eradication, antibiotic resistance, randomized clinical trial

##plugins.themes.academic_pro.article.details##

References

  1. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection. The Maastricht III Consensus Report. Gut 2007;102:1-18.
  2. William D, Benjamin CY. American College of Gastroenterology Guidelines on the Management of Helicobacter pylori Infection. Am J Gastroenterol 2007;102:1808-25.
  3. De Korwin J-D. Helicobacter pylori infection and antimicrobial agents resistance. Rev Med Intern 2004;(25):54-64.
  4. Ben Mansour K, Burucoa C, Zribi M, et al. Primary resistance to clarithromycin, metronidazole and amoxicillin of Helicobacter isolated from Tunisian patients with peptic ulcers and gastritis: a prospective multicentre study. Ann Clin Microbiol Antimicrob. 2010; 9:22-8.
  5. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International workshop on the Histopathology of gastritis Houston 1994. Am J Surg Pathol 1996; 20:1161-81.
  6. Loivukene K, Maaroos HI, Kolk H, Kull I, Labotkin K, Mikelsaar M. Prevalence of antibiotic resistance of Helicobacter pylori isolates in Estonia during 1995-2000 in comparison to the consumption of antibiotics used in treatment regims. Clin Microbiol Infect 2002;8:598-603.
  7. Poon SK, Chang CS, Su J, et al. Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lanzoprazole-based triple therapy. Aliment Pharmacol Ther 2002;16: 291-6.
  8. Megraud F. H pylori antibiotic resistance: prevalence, importance and advances in testing. Gut 2004;53:1374-84.
  9. Perez Aldana L, Kato M, Nakagawa S, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 2002; 7: 306-9.
  10. Meyer JM, silliman NP, Wang W, et al. Risk factors of Helicobacter pylori resistance in the United States: the surveillance of H pylori anti-microbial resistance partnership (sharp) study 1993-1999. Ann Intern Med 2002;136: 1-39.
  11. Kantarçeken B, Yildirim B, Karincaoglu M, Aladag M, Himioglu F. Helicobacter pylori and antibiotic resistance. Turk J Gastroenterol 2000;11: 141-5.
  12. Momenah A, Asghar AH. Prevalence and antibiotic resistance among Helicobacter pylori clinical isolates from main hospitals in the western region of Saudi Arabia. Pak J Med Sci 2008;24: 100-3.
  13. Kohanteb J, Bazargani A, Saberi-Firoozi M, Mobasser A. Antimicrobial susceptibility testing of Helicobacter pylori to selected agents by agar dilution method in Shiraz-Iran. Indian J Med Microbiol 2007;25: 374-7.
  14. SecK A, Mbengue M, Gassama-Sow A, Diouf A, Mourtalla Ka, Saad-Bouh Boye Ch. Antibiotic susceptibility of Helicobacter pylori isolates in Dakar, Senegal. J Infect Developing Countries 2009;3:137-40.
  15. Gumurdulu Y, Serin E, Ozer B, at al. Low eradication of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. World J Gastroenterol 2004;10: 668-71.
  16. Wei-Hao Sun, Xi-Long Ou, Da-Zhong Cao, et al. Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients. World J Gastroenterol 2005;11: 2477-81.
  17. Amrani N, Kanouni N, Bennani M, Serraj I. Helicobacter pylori eradication: which first intention tri-therapy? Acta Endoscopica 2003;33: 371-4.
  18. Lahbadi M, Lahmidani A, El Mekkaoui N, et al. Eradication de l'Helicobacter pylori au Maroc: quelle trithérapie en première intention? Gastroenterol Clin Biol 2008;32:A206.
  19. Onder G, Aydin A, Akarca U, Tekin F, Ozutemiz O, Ilter T. High Helicobacter pylori resistance rate to clarithromycin in Turkey. J Clin Gastroenterol 2007; 41:747-50.